Medical Licensing (MD/DO) · Independent exam preparation
Complex General Surgical Oncology Qualifying Examination: Decision-Focused Preparation Study Guide
Practise cancer staging, resectability, operative selection, multidisciplinary sequencing, and evidence interpretation for the ABS CGSO Qualifying Examination.
By CertMedbry · Updated 18 October 2026
Practise deciding which findings change an operation, when systemic treatment should precede surgery, and how pathology, organ reserve, and patient goals alter cancer care. This guide develops 60 selected concepts across all 16 official domains, with original questions and recall cards. Selected postoperative complication decisions, a colorectal surveillance pathway, and breast rehabilitation are included. The American Board of Surgery outline defines the full examination scope; this selective guide does not exhaust its diseases, procedures, complications, surveillance pathways, or rehabilitation needs.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Where does the Qualifying Examination fit in CGSO certification?
The ABS identifies the Complex General Surgical Oncology Qualifying Examination as the first of two examinations for CGSO board certification. Passing permits progression to the separate Certifying Examination. It is advanced specialty certification, not an initial physician-licensing examination.
How many questions are there, and how much time is provided?
ABS describes approximately 200 multiple-choice questions over approximately five hours. The examination has three 90-minute sessions, with optional breaks after the first two sessions. Once a session is completed, candidates cannot return to its questions. The approximate question count does not establish a separate scored-question or pretest-question count.
How is the examination delivered?
ABS describes computer-based delivery at Pearson test centers and provides Pearson scheduling information. Candidates complete three 90-minute sessions, may take optional breaks after sessions one and two, and cannot return to a completed session. The examination uses multiple-choice questions; the cited description does not establish adaptive testing or additional item styles. The 20 questions here are independent four-option, single-best-answer learning drills and do not predict passing.
Which blueprint and dates apply to this guide?
The ABS-linked five-page blueprint is marked Updated 01/2023 and describes a revision undertaken in 2022. It remained the linked outline when verified on October 9, 2026. No separate effective date is stated. The blueprint primarily applies to the Qualifying Examination; its date should not be represented as a newly issued 2026 syllabus.
ABS: Exam Content Outlines · ABS: CGSO Exam Blueprint, Updated 01/2023
How are the official content domains weighted?
Approximate whole-examination targets are Breast 12%, Colorectal 12%, Cutaneous 11%, Endocrine 9%, Hepatopancreatobiliary 14%, Sarcoma 10%, Peritoneal Malignancy 7%, Thoracic 5%, and Upper Gastrointestinal 8%, together comprising Patient Care at 88%. The remaining 12% comprises Medical Oncology 2%, Pathology 2%, Radiation Oncology 1%, Clinical Trials 2%, End of Life/Palliative Care 2%, Systems-Based Practice 2%, and Community Outreach 1%. Small learning sets require rounding.
How should the patient-care dimension percentages be interpreted?
The second blueprint table applies only within the 88% Patient Care section. It spans epidemiology, pathology, screening and genetic counseling, diagnostic workup, imaging, preoperative evaluation and care, intraoperative management, functional and cosmetic optimization, postoperative treatment and complications, surveillance, outcomes, rehabilitation, palliation, and equity. Those percentages are a second view of Patient Care and should not be added to the whole-examination domain percentages.
Does this guide cover the complete official outline?
No. Its 60 concepts include every official domain, with greater space for domains carrying greater approximate weight. The official outline remains the full scope, including topics not developed here, such as additional endocrine tumors, anal neoplasms, Merkel cell carcinoma, pulmonary metastases, and additional peritoneal histologies. The selected complication, surveillance, and rehabilitation examples also require further disease-specific study.
This guide addresses the American Board of Surgery Complex General Surgical Oncology Qualifying Examination, an advanced surgical specialty board certification examination in the United States. It is the cognitive examination preceding the separate Certifying Examination. These independent educational materials are not ABS examination items or an endorsement by ABS.
Outline used: Current ABS-linked Complex General Surgical Oncology Exam Blueprint, marked Updated 01/2023, verified on 2026-10-09. The document describes a 2022 revision and primarily applies to the Qualifying Examination; no separate effective date is stated. The workbook's provider-prefixed label maps directly to the official examination name.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Breast12%
1.What margin is adequate after breast conservation for invasive carcinoma?
For invasive breast carcinoma treated with breast-conserving surgery and whole-breast irradiation, an adequate negative margin is no ink on invasive carcinoma or associated ductal carcinoma in situ. Wider negative margins have not shown additional reduction in ipsilateral recurrence. Tumor on ink indicates a positive margin and a materially different local-control problem. The standard depends on this treatment setting; it does not automatically establish the margin requirement for pure ductal carcinoma in situ.
Apply it
A patient has a small invasive carcinoma excised with no tumor on ink and a closest margin of 1 mm. Whole-breast irradiation is planned. Assess the margin as negative without requiring another operation solely to increase its width.
Common pitfall: Do not substitute an arbitrary wider distance for the invasive-cancer standard, or transfer that standard unchanged to pure ductal carcinoma in situ.
SSO–ASTRO Consensus Guideline: Margins for Breast-Conserving Surgery
2.How should an additional suspicious breast MRI lesion change planning?
Breast MRI can reveal additional ipsilateral or contralateral abnormalities, but enhancement is not equivalent to malignancy. A suspicious finding that would expand surgery should undergo targeted evaluation and tissue confirmation when feasible. MRI can improve anatomic assessment while also producing false-positive findings. The discriminating question is whether the additional lesion is proven cancer and changes the ability to obtain satisfactory local control, rather than whether it merely appears on a more sensitive imaging study.
Apply it
A patient eligible for lumpectomy has a separate enhancing focus on MRI without an ultrasound correlate. Arrange MRI-directed sampling before recommending mastectomy based on presumed multicentric disease or assuming the additional focus is benign.
Common pitfall: Treating every enhancing focus as cancer can create avoidable surgical escalation; ignoring a suspicious focus can leave a clinically important second lesion uncharacterized.
3.Which breast biomarkers predict benefit from targeted systemic treatment?
Estrogen receptor and progesterone receptor assessment identifies hormone-responsive biology, while HER2 testing identifies tumors potentially responsive to HER2-directed treatment. These are predictive features because they help select therapy, although they also carry prognostic information. Tumor size, nodal status, grade, and patient factors remain relevant to treatment intensity. Distinguish identifying a treatment target from proving that a particular patient needs every available agent or that favorable biology eliminates local treatment requirements.
Apply it
Two patients have similarly sized invasive breast cancers, but one tumor is strongly estrogen receptor positive and the other is HER2 positive. Build different systemic treatment discussions around the demonstrated targets while retaining stage-based surgical assessment.
Common pitfall: Anatomic stage alone cannot select endocrine or HER2-directed treatment, and receptor positivity does not make surgery or appropriate radiation automatically unnecessary in localized disease.
4.Which criteria distinguish inflammatory breast cancer, and why does treatment usually precede surgery?
Inflammatory breast cancer requires rapid development of inflammatory breast symptoms within six months, erythema involving at least one-third of the breast, and pathological confirmation of invasive carcinoma. Edema and peau d'orange are characteristic; a discrete mass is unnecessary. Dermal lymphatic tumor emboli support the diagnosis but are not required, because sampling can miss them. These criteria distinguish the syndrome from a longstanding locally advanced tumor with limited secondary skin changes. Nonmetastatic disease generally receives systemic treatment first, followed by appropriate mastectomy and radiation. [International diagnostic consensus](https://pmc.ncbi.nlm.nih.gov/articles/PMC3105293/)
Apply it
A patient develops erythema and edema across half the breast over six weeks. Core biopsy confirms invasive carcinoma, while skin biopsy shows no dermal emboli. The negative skin sample does not exclude inflammatory breast cancer; stage the disease and begin multidisciplinary systemic treatment.
Common pitfall: Erythema alone is insufficient. Establish its extent, rapid onset, and invasive histology; persistent suspicious changes should not be managed with repeated antibiotics without diagnostic assessment.
5.When should arm swelling after breast cancer treatment trigger rehabilitation?
Persistent ipsilateral arm swelling, heaviness, and reduced movement after axillary surgery or radiation suggest impaired lymphatic drainage. Assess for competing causes, including infection, thrombosis, and recurrent disease, before attributing swelling to lymphedema. Once established, refer for lymphedema rehabilitation using fitted compression, skin care, and individualized progressive exercise, with manual techniques when indicated. Compression limits fluid accumulation, while muscle activity supports lymphatic flow and functional recovery. [NCI lymphedema guidance](https://www.cancer.gov/about-cancer/treatment/side-effects/lymphedema/lymphedema-hp-pdq)
Apply it
Months after axillary treatment, a patient has persistent arm heaviness and restricted shoulder motion without acute erythema or fever. Evaluate the swelling, then arrange therapist-directed compression and graded movement to improve function.
Common pitfall: Do not prescribe permanent arm inactivity. New redness, warmth, fever, or abrupt swelling requires assessment for an acute cause before routine rehabilitation.
6.Which breast cancer patients can omit sentinel lymph node biopsy, and how does this differ from omitting completion axillary dissection?
ASCO's 2025 guideline permits sentinel lymph node biopsy omission when all specified conditions are met: postmenopausal status, age at least 50 years, unifocal invasive ductal carcinoma no larger than 2 cm, Nottingham grade 1–2, hormone receptor-positive/HER2-negative disease, intended adjuvant endocrine therapy, and upfront breast-conserving surgery. Preoperative axillary ultrasound must show no suspicious nodes, or only one suspicious node with benign, imaging-concordant biopsy findings. Detecting sentinel node metastasis must not change treatment recommendations. Patients younger than 65 must plan whole-breast irradiation; qualifying patients aged at least 65 may also consider radiation omission under the guideline's separate good-practice statement. Completion-dissection omission is a different pathway: patients have already undergone sentinel biopsy. In the classic setting, clinically node-negative cT1–T2 cancers with one or two positive sentinel nodes treated by breast conservation and whole-breast irradiation can avoid completion axillary dissection.
Apply it
A 62-year-old postmenopausal patient has a unifocal 1.3 cm Nottingham grade 1 invasive ductal carcinoma that is hormone receptor-positive and HER2-negative. Examination and preoperative axillary ultrasound show no suspicious nodes. She plans upfront lumpectomy, whole-breast irradiation, and adjuvant endocrine therapy. Sentinel biopsy may be omitted after confirming that a positive sentinel node would not change systemic or radiation recommendations. Her age makes the planned whole-breast irradiation an explicit eligibility requirement.
Common pitfall: A negative axillary ultrasound does not prove pathological node negativity. Omission accepts some uncertainty because nodal information would not change treatment in the selected population. Do not extend these criteria automatically to lobular histology, multifocal disease, neoadjuvant treatment, or mastectomy. Avoiding completion dissection after a positive sentinel biopsy requires its own assessment.
NCI: Breast Cancer Treatment, Health Professional Version · park-et-al-2025-sentinel-lymph-node-biopsy-in-early-stage-breast-cancer-asco-guideline-update.pdf
7.How should hormone receptor positivity guide male breast cancer treatment?
Male breast cancer requires assessment of invasive histology, anatomic extent, and predictive biomarkers. Tamoxifen is the usual adjuvant endocrine choice for suitable patients with hormone receptor-positive disease. If tamoxifen is contraindicated and an aromatase inhibitor is used, it should be combined with gonadal suppression using a GnRH analogue; aromatase inhibitor monotherapy is not recommended. Surgical and additional systemic treatment decisions still depend on stage, regional nodes, comorbidity, and tolerance.
Apply it
A man has resected estrogen receptor-positive invasive breast cancer. Discuss adjuvant tamoxifen. If a contraindication prevents its use, assess an aromatase inhibitor with gonadal suppression rather than substituting an aromatase inhibitor alone.
Common pitfall: Do not omit endocrine treatment because the patient is male, or assume that aromatase inhibitor monotherapy has the same role as in a postmenopausal woman.
Colorectal12%
8.Why does colon cancer staging require adequate regional node evaluation?
Regional lymph node evaluation distinguishes node-negative from node-positive colon cancer and influences prognosis and adjuvant treatment. Examination of at least 12 nodes is a commonly used adequacy benchmark. A low yield raises concern for understaging, although patient, tumor, treatment, surgical, and pathology factors can influence the count. The number of examined nodes is different from the number involved. A report with few negative nodes cannot provide the same confidence as a well-assessed regional specimen.
Apply it
A colectomy specimen contains a tumor extending through the muscularis propria and only five negative nodes. Review specimen evaluation with pathology and recognize the staging limitation before describing the case as securely low-risk node-negative disease.
Common pitfall: A low node count does not itself prove nodal metastasis, but accepting it without scrutiny can make an apparently favorable stage misleading for postoperative decisions.
9.Why is adjuvant chemotherapy considered after resection of stage III colon cancer?
Stage III colon cancer includes regional nodal metastasis without distant metastasis. Even after complete removal of visible disease, occult systemic disease creates a recurrence risk that adjuvant chemotherapy can reduce. Fluoropyrimidine-based treatment with oxaliplatin is an established option for suitable patients. Choice and duration depend on recurrence risk, functional status, neuropathy risk, and regimen. A negative surgical margin addresses local completeness; it does not erase the systemic implication of involved regional nodes.
Apply it
A fit patient has an R0 colectomy with two involved regional nodes and no distant disease. Discuss postoperative systemic treatment despite complete visible resection, incorporating neuropathy concerns and the pathologic risk profile into regimen planning.
Common pitfall: Do not treat complete resection as proof that systemic treatment has no role, or mistake regional nodal involvement for automatically unresectable metastatic disease.
10.How does mismatch repair status change stage II colon cancer treatment?
Stage II mismatch repair-deficient (dMMR)/MSI-high colon cancer generally has a favorable prognosis, and fluoropyrimidine-only adjuvant chemotherapy should not routinely be offered because benefit has not been demonstrated in this subgroup. Adverse findings warranting an adjuvant discussion include T4 disease, fewer than 12 examined lymph nodes, lymphovascular or perineural invasion, intestinal obstruction, tumor perforation, and high-grade tumor budding. Poor differentiation alone is not considered a high-risk prognostic feature in dMMR disease. If these other findings lead to a shared decision to administer chemotherapy, an oxaliplatin-containing regimen is recommended rather than fluoropyrimidine monotherapy. Evidence supporting benefit specifically in high-risk stage II dMMR disease is limited and partly indirect; discuss this uncertainty and cumulative peripheral neuropathy. See the ASCO stage II colon cancer guideline: https://ascopubs.org/doi/10.1200/JCO.21.02538.
Apply it
After complete resection, a patient with poorly differentiated T3N0 dMMR cancer, 18 negative nodes, and no invasion, obstruction, perforation, or high-grade budding generally proceeds to surveillance; poor differentiation alone does not reverse the favorable molecular assessment. In contrast, T4aN0 dMMR cancer with only eight examined nodes and lymphovascular invasion warrants discussion of an oxaliplatin-containing regimen because serosal penetration, possible understaging, and vascular invasion increase concern for recurrence.
Common pitfall: Do not apply the usual adverse interpretation of poor differentiation automatically to dMMR tumors. Conversely, favorable dMMR biology does not eliminate the significance of T4 disease or inadequate nodal evaluation. Neither the presence of adverse features nor uncertainty about oxaliplatin benefit establishes a role for fluoropyrimidine monotherapy.
11.What does pelvic MRI add to rectal cancer staging?
Pelvic MRI defines the relationship of a rectal tumor to the mesorectal compartment, mesorectal fascia, and adjacent structures. These findings help estimate circumferential margin risk and guide multidisciplinary sequencing. Colonoscopy establishes mucosal location and enables biopsy, while distant staging evaluates systemic spread; neither replaces detailed pelvic assessment. The discriminating issue is whether local anatomy threatens an adequate oncologic plane, not simply whether the primary tumor has been visualized by some imaging modality.
Apply it
A biopsy-proven mid-rectal cancer has no distant metastases on staging CT. Obtain pelvic MRI to assess local extent and the mesorectal fascia before selecting immediate surgery or a preoperative treatment strategy for this patient.
Common pitfall: A normal distant staging study does not establish a safe circumferential margin, and tumor distance from the anal verge alone cannot describe local resectability.
12.Why is the mesorectal plane central to rectal cancer surgery?
The mesorectum contains lymphatic drainage and potential tumor deposits surrounding the rectum. An oncologic mesorectal excision removes this envelope in an appropriate fascial plane while seeking clear circumferential and distal margins. Total mesorectal excision is particularly important for middle and lower rectal tumors. Its quality influences local control. The principle concerns the completeness and plane of the specimen, not merely the length of bowel removed or whether the operation uses an open or minimally invasive approach.
Apply it
A lower rectal tumor requires radical resection. Plan dissection that preserves the integrity of the mesorectal envelope and assess the specimen and circumferential margin rather than judging oncologic quality only by distal bowel length.
Common pitfall: Removing a long segment of rectum does not compensate for an incomplete mesorectal plane, and technical access alone does not establish equivalent specimen quality.
13.Which rectal cancers are favorable candidates for curative local excision?
Typical selection requires cT1N0 adenocarcinoma smaller than 3 cm, involving less than 30% of the rectal circumference, well or moderately differentiated, and accessible for full-thickness excision with clear margins. Biopsy should show no adverse features such as lymphovascular or perineural invasion or tumor budding. Local excision does not remove mesorectal nodes. Deeper invasion, positive margins, poor differentiation, or other adverse pathology generally prompts consideration of completion radical resection in a fit patient because local treatment may leave regional disease untreated.
Apply it
A 2 cm cT1N0 lesion occupying 20% of the circumference has favorable biopsy findings and is accessible transanally. Local excision may be reasonable. If the specimen instead shows T2 invasion or lymphovascular invasion, discuss completion radical resection.
Common pitfall: Accessibility and a desire to avoid a stoma do not establish low nodal risk. Final pathology can overturn the initial local-treatment plan.
Management of Rectal Cancer (2020) | ASCRS Toolkit - FREE Resources
14.What surveillance schedule follows curative treatment of stage II or III colon cancer?
Surveillance should target patients fit and willing to receive treatment for recurrence. The ASCRS expanded follow-up resource provides an attributed schedule: clinical visits every 3–6 months during years 1–3 and every 6 months during years 4–5. Its narrative specifies CEA approximately every 3 months for the first 2 years, then every 6 months for another 3 years. It describes annual chest/abdomen/pelvis CT; its displayed schedule specifies annual imaging during years 1–3, with imaging during years 4–5 individualized. Guideline schedules vary in testing frequency and whether routine CT continues for 3 or 5 years, so this resource's schedule should not be treated as universal. After complete perioperative colonic clearance, perform colonoscopy at 1 year, then 3 years later, then every 5 years if findings remain normal. If obstruction prevented preoperative clearance, complete colonoscopy within 3–6 months after surgery. Colonoscopy detects metachronous neoplasia and intraluminal disease; CEA and imaging address extraintestinal recurrence.
Apply it
A fit patient completes curative treatment for stage III colon cancer. Arrange the first clinical review and CEA measurement within about 3 months, annual CT during the initial surveillance years, and colonoscopy at 1 year after surgery. If the 1-year colonoscopy is normal, schedule the next examination 3 years later. A sustained CEA increase warrants assessment for recurrence immediately, including hepatic and pulmonary disease, even when colonoscopy was recently normal.
Common pitfall: Do not wait for a scheduled examination when new symptoms or a sustained CEA rise develops. Normal CEA does not exclude recurrence, and normal colonoscopy cannot exclude liver, lung, or extraluminal disease. Continue surveillance only while its findings could meaningfully alter care; colonoscopy intervals also change when significant polyps are found.
NCI: Colon Cancer Treatment, Health Professional Version · Colon and Rectal Cancer Follow-Up Care Expanded Version
Cutaneous11%
15.Why is Breslow thickness essential in melanoma assessment?
Breslow thickness measures vertical invasion of a primary melanoma and is central to risk assessment, excision planning, and discussion of sentinel node staging. Ulceration adds prognostic information. The pathology specimen must permit reliable depth measurement; a transected lesion can leave the true maximum thickness uncertain. Surface diameter, pigmentation, and patient-reported duration cannot substitute for invasive depth. Distinguish the depth of the malignant lesion from the thickness of surrounding normal skin or the size of the biopsy specimen.
Apply it
A small pigmented lesion proves to be a thick invasive melanoma on complete histologic assessment. Base staging and surgical discussion on measured thickness and ulceration rather than reassuring the patient because its surface diameter was modest.
Common pitfall: A small visible footprint can conceal substantial invasion, and a superficially transected biopsy should not be interpreted as establishing the final maximum tumor depth.
16.How does melanoma thickness guide wide excision margins?
Wide local excision removes the melanoma biopsy site with a clinical margin selected according to invasive thickness. A 2 cm margin is appropriate for melanomas thicker than 2 mm when anatomically feasible; thinner tumors generally require narrower margins. The margin is measured clinically around the lesion or biopsy scar, not inferred from a microscopic clearance measurement alone. Functional constraints may require specialist planning, but increasing the margin indefinitely does not create unlimited additional oncologic benefit.
Apply it
A patient has a 2.4 mm invasive melanoma on the trunk with sufficient surrounding tissue for closure. Plan wide excision with a 2 cm clinical margin and address nodal staging as a separate decision.
Common pitfall: Do not select the margin from surface diameter, or assume a negative diagnostic biopsy margin eliminates the need for thickness-appropriate definitive wide excision.
17.Which melanoma thickness and ulceration findings guide sentinel node biopsy?
For clinically node-negative melanoma, routine sentinel biopsy is omitted for T1a lesions: nonulcerated tumors below 0.8 mm. Discuss it individually for T1b disease, comprising tumors 0.8–1.0 mm or ulcerated tumors below 0.8 mm. Sentinel biopsy is recommended for intermediate-thickness tumors above 1.0 through 4.0 mm. For tumors thicker than 4.0 mm, it may be recommended after discussing staging value, competing distant-metastatic risk, and management implications. A suspicious palpable node instead requires direct diagnostic assessment. [ASCO–SSO guideline](https://pubmed.ncbi.nlm.nih.gov/29232171/)
Apply it
A nonulcerated 0.6 mm melanoma ordinarily does not require sentinel biopsy. An ulcerated 0.7 mm lesion warrants discussion, while a clinically node-negative 1.6 mm lesion meets the intermediate-thickness recommendation.
Common pitfall: Do not use thickness without ulceration for thin lesions, or promise that sentinel biopsy itself guarantees a survival benefit.
18.Why does a positive melanoma sentinel node not automatically require completion dissection?
Trials comparing immediate completion lymph node dissection with nodal observation after a positive melanoma sentinel node did not demonstrate a melanoma-specific survival advantage for routine completion dissection. Dissection can improve regional control but increases morbidity, particularly lymphedema. For suitable patients, active nodal surveillance with ultrasound is an alternative. Observation requires reliable follow-up and appropriate expertise; it is an organized management strategy, not abandonment of regional assessment after obtaining a positive staging result.
Apply it
A patient has a microscopic melanoma deposit in a sentinel node and no clinically evident residual nodal disease. Discuss ultrasound-based surveillance, regional control, and morbidity alongside systemic treatment considerations rather than scheduling automatic completion dissection.
Common pitfall: Do not equate surveillance with no follow-up, or extend evidence concerning microscopic sentinel disease without qualification to bulky, symptomatic, clinically apparent nodal metastases.
19.Which cutaneous squamous cell carcinoma findings require greater oncologic concern?
Poor differentiation, deep invasion, perineural invasion, immunosuppression, and high-risk sites such as the ear or lip increase concern for recurrence or spread. Examine regional nodes and select treatment that establishes margin clearance; Mohs surgery can be useful for high-risk, poorly defined tumors. [NCI skin cancer treatment](https://www.cancer.gov/types/skin/hp/skin-treatment-pdq)
Apply it
An ear squamous carcinoma shows perineural invasion. Arrange specialist assessment of extent and regional nodes and plan margin-controlled treatment rather than routine destructive therapy.
Common pitfall: A small diameter does not neutralize adverse histology or immunosuppression.
20.Why can basal cell carcinoma require meticulous local treatment despite rare metastasis?
Basal cell carcinoma rarely metastasizes but can destroy adjacent tissue. Recurrent, central facial, or morpheaform lesions may have poorly defined extensions. Mohs surgery combines margin assessment with tissue preservation where functional or cosmetic loss matters. [NCI skin cancer treatment](https://www.cancer.gov/types/skin/hp/skin-treatment-pdq)
Apply it
A recurrent nasal basal cell carcinoma has indistinct borders. Consider Mohs surgery to establish clearance while preserving tissue needed for reconstruction.
Common pitfall: Low metastatic risk does not justify observing a progressively destructive lesion or treating it without attention to margins.
Endocrine9%
21.What do calcitonin and RET testing contribute in medullary thyroid carcinoma?
Medullary thyroid carcinoma arises from parafollicular C cells, making calcitonin a relevant biochemical marker. Germline RET testing identifies hereditary disease and can reveal implications for relatives and associated endocrine tumors. A tumor's apparently sporadic presentation does not reliably exclude an inherited variant. Distinguish a marker used to assess tumor activity from a germline result used to establish inherited susceptibility. These findings inform counseling and evaluation but do not replace anatomic staging of the primary and regional disease.
Apply it
An adult with newly diagnosed medullary thyroid carcinoma reports no family history. Arrange germline RET evaluation and appropriate biochemical assessment rather than labeling the tumor sporadic solely because relatives have no known thyroid cancer.
Common pitfall: Do not treat calcitonin as interchangeable with thyroglobulin, or use an absent family history to rule out a germline RET-associated syndrome.
22.Why must pheochromocytoma be addressed before thyroid surgery in MEN2?
MEN2 can combine medullary thyroid carcinoma with pheochromocytoma. An unrecognized catecholamine-secreting tumor creates substantial hemodynamic danger during anesthesia and surgery. Evaluation for pheochromocytoma therefore matters before thyroid intervention, and an identified functional adrenal tumor generally requires appropriate preparation and treatment first. The sequence is driven by immediate physiologic risk rather than by which lesion first brought the patient to attention. A normal office blood pressure does not reliably exclude episodic catecholamine secretion.
Apply it
A patient with RET-associated medullary thyroid carcinoma also has episodic palpitations and an adrenal mass. Evaluate catecholamine secretion and organize treatment of a confirmed pheochromocytoma before proceeding directly to the planned thyroid operation.
Common pitfall: Prioritizing the thyroid cancer solely because it is malignant can expose the patient to an avoidable catecholamine crisis from an untreated associated adrenal tumor.
NCI: Thyroid Cancer Treatment, Health Professional Version · NCI: Pheochromocytoma and Paraganglioma Treatment, Health Professional Version
23.Which biochemical tests evaluate suspected pheochromocytoma?
Plasma free metanephrines or urinary fractionated metanephrines are central biochemical tests for suspected pheochromocytoma or paraganglioma. These metabolites help identify catecholamine production that may be episodic clinically. Test interpretation requires attention to collection conditions, medications, and the degree of elevation. Imaging localizes a lesion but does not alone establish its secretory behavior. When a catecholamine-producing tumor is plausible, biochemical evaluation should precede invasive manipulation that could provoke dangerous release.
Apply it
A patient has an adrenal mass with spells of headache, diaphoresis, and palpitations. Obtain appropriate metanephrine testing before considering needle sampling, and interpret any borderline result in light of testing conditions and potential interfering factors.
Common pitfall: Do not regard a single normal blood pressure reading as exclusionary, or approach a suspicious adrenal lesion as a routine biopsy target before biochemical assessment.
NCI: Pheochromocytoma and Paraganglioma Treatment, Health Professional Version
24.Why must alpha blockade precede beta blockade in pheochromocytoma preparation?
Catecholamine excess can cause marked alpha-mediated vasoconstriction and beta-mediated tachycardia. Preoperative alpha-adrenergic blockade reduces vasoconstrictive risk; beta blockade may then be added when needed for persistent tachycardia. Starting beta blockade first can leave alpha effects unopposed and worsen hypertension. Volume status also requires attention because chronic vasoconstriction can coexist with intravascular depletion. The sequence is a physiologic safety requirement, not merely a preference between two equivalent antihypertensive drug classes.
Apply it
A patient with confirmed pheochromocytoma remains tachycardic during operative preparation. Establish adequate alpha blockade and assess volume status before adding beta blockade, rather than treating the pulse rate first with an isolated beta blocker.
Common pitfall: A lower heart rate does not guarantee safer preparation if severe vasoconstriction persists; beta blockade alone can intensify the underlying catecholamine-related hemodynamic problem.
NCI: Pheochromocytoma and Paraganglioma Treatment, Health Professional Version
25.Why is radioactive iodine useful in selected differentiated thyroid cancers but not medullary carcinoma?
Selected differentiated thyroid cancers retain follicular-cell functions that permit radioactive iodine uptake, creating a treatment mechanism after appropriate surgery. Medullary thyroid carcinoma arises from C cells and lacks that same therapeutic basis. Histologic lineage therefore changes postoperative options even when both tumors occur in the thyroid. Radioactive iodine is not automatically indicated for every differentiated cancer either; recurrence risk, disease extent, and expected benefit determine its role rather than thyroid location alone.
Apply it
Two patients undergo thyroid surgery, one for differentiated follicular-cell carcinoma and one for medullary carcinoma. Discuss radioactive iodine selectively for the differentiated tumor while using a different postoperative strategy for the C-cell malignancy.
Common pitfall: Do not assume all thyroid cancers concentrate iodine, or replace risk assessment with automatic radioactive iodine treatment merely because total thyroidectomy has been performed.
Hepatopancreatobiliary14%
26.When can characteristic imaging establish hepatocellular carcinoma?
ACR CT/MRI LI-RADS v2018 permits noninvasive HCC diagnosis in its eligible at-risk population, including eligible adults with cirrhosis, when technically adequate multiphasic CT or MRI meets LR-5 criteria. A 10–19 mm observation with nonrim arterial phase hyperenhancement and nonperipheral washout can qualify as LR-5 without an enhancing capsule or threshold growth. The inclusive minimum size is 10 mm: an observation measuring exactly 10 mm can qualify. Subcentimeter observations cannot be LR-5 and generally require short-interval follow-up because definitive imaging characterization is less reliable. These diagnostic rules cannot simply be transferred to patients outside the eligible risk population.
Apply it
An exactly 10 mm observation in an eligible adult with cirrhosis shows nonrim arterial hyperenhancement and nonperipheral portal venous washout on adequate multiphasic CT. It can meet LR-5 criteria. An otherwise similar 7 mm observation cannot be LR-5 and generally requires follow-up rather than definitive labeling.
Common pitfall: Do not interpret the threshold as requiring a lesion to exceed 10 mm. Size alone, a single contrast phase, rim enhancement, or an enhancing mass outside the eligible risk population does not establish LR-5.
NCI: Primary Liver Cancer Treatment, Health Professional Version · What's New in v2018 : RADS - Reporting and Data Systems Support
27.Why does functional liver reserve determine HCC operability?
HCC treatment must address both the cancer and the liver that will remain after treatment. A technically removable lesion may still be unsuitable for resection when cirrhosis, portal hypertension, or impaired hepatic function creates excessive postoperative liver-failure risk. Tumor distribution and vascular involvement matter alongside hepatic reserve. The important distinction is between an anatomically possible resection and a physiologically tolerable one. Preserving enough functioning liver is essential even when a wide tumor clearance appears achievable.
Apply it
A patient has a solitary peripheral HCC but also ascites and substantial portal hypertension. Evaluate hepatic reserve and alternative treatment pathways instead of recommending partial hepatectomy solely because the lesion is easy to reach surgically.
Common pitfall: A small tumor does not guarantee safe hepatectomy, and normal-appearing remaining liver volume does not prove that the remnant has adequate functional capacity.
NCI: Primary Liver Cancer Treatment, Health Professional Version
28.How do Milan criteria guide HCC transplant selection?
The Milan framework permits one HCC lesion no larger than 5 cm or up to three lesions, each no larger than 3 cm, without macrovascular invasion or extrahepatic spread. Transplantation can address both eligible cancer and the diseased liver, whereas resection leaves the underlying hepatic disease. Milan criteria describe tumor selection; they are not identical to organ-allocation rules, waiting-list priority, or overall medical eligibility. Meeting them supports transplant assessment but does not guarantee listing or an organ.
Apply it
A patient with decompensated cirrhosis has three HCC lesions measuring 2.8, 2.4, and 1.9 cm, without vascular invasion or extrahepatic disease. The tumor burden meets Milan criteria. A fourth lesion or a 3.5 cm lesion among three would exceed this framework.
Common pitfall: Do not apply the single-lesion 5 cm limit separately to multiple tumors, or confuse clinical tumor eligibility with allocation priority and transplant fitness.
NCI: Primary Liver Cancer Treatment, Health Professional Version
29.Which pancreatic cancers are treated with pancreaticoduodenectomy?
Pancreaticoduodenectomy is the principal resection for suitable cancers of the pancreatic head region because the head shares close anatomic relationships with the duodenum and distal bile duct. Selection requires assessment of distant disease, vascular relationships, physiologic fitness, and the probability of a complete oncologic resection. The operation is not chosen simply because jaundice is present. Distinguish the location-based operation from the broader decision of whether the patient's cancer and condition justify major pancreatic surgery.
Apply it
A fit patient has a localized pancreatic head adenocarcinoma without distant spread or prohibitive vascular involvement. Evaluate pancreaticoduodenectomy within multidisciplinary planning rather than choosing a distal operation or assuming biliary drainage alone is definitive treatment.
Common pitfall: Do not let tumor location substitute for resectability assessment, or interpret relief of obstructive jaundice as treatment of the underlying pancreatic malignancy itself.
NCI: Pancreatic Cancer Treatment, Health Professional Version
30.Which findings after pancreatic resection suggest a clinically relevant pancreatic fistula?
Drain fluid amylase exceeding three times the institutional upper limit of normal serum amylase on or after postoperative day three supports a pancreatic leak. A clinically relevant fistula additionally causes a related clinical consequence or change in management; an isolated biochemical leak is insufficient. Fever, inflammatory deterioration, abdominal pain, or an associated collection should trigger assessment for infection and inadequate drainage. CT and prompt drainage of clinically significant collections, with antibiotics when infection is suspected, aim to prevent sepsis and hemorrhagic complications. [ISGPS definition](https://pubmed.ncbi.nlm.nih.gov/28040257/); [PORSCH management algorithm](https://link.springer.com/article/10.1186/s13063-020-4167-9)
Apply it
On day five after pancreaticoduodenectomy, a patient develops fever and rising inflammatory markers with amylase-rich drain output. Obtain imaging and assess source control; an infected undrained collection warrants drainage and antimicrobial treatment rather than observation based only on stable drain volume.
Common pitfall: Do not equate every elevated drain amylase with a clinically relevant fistula, or remove a drain solely because output is low while clinical deterioration suggests an undrained collection.
31.Why can CA 19-9 mislead pancreatic cancer assessment?
CA 19-9 can support assessment and longitudinal monitoring of pancreatic cancer, but it is neither sufficiently specific nor universally expressed to establish or exclude the diagnosis alone. Biliary obstruction can elevate the value, and some patients do not produce the marker. Interpret a measurement alongside bilirubin, imaging, histology when required, and the clinical course. Changes after relief of obstruction may clarify interpretation, but a marker trend never replaces direct assessment of disease extent and resectability.
Apply it
A patient with a pancreatic head mass has obstructive jaundice and a markedly elevated CA 19-9. Interpret the marker in that context and reassess appropriately after obstruction is addressed, while continuing definitive staging and diagnostic evaluation.
Common pitfall: Do not declare metastatic or unresectable disease from CA 19-9 alone, and do not exclude pancreatic cancer because a patient's marker remains normal.
NCI: Pancreatic Cancer Treatment, Health Professional Version
32.When does biliary decompression provide palliation in pancreatic cancer?
Unresectable pancreatic cancer may cause biliary obstruction that produces pruritus, jaundice, infection risk, and barriers to systemic treatment. Endoscopic or other appropriate biliary drainage can relieve obstruction without removing the primary tumor. The choice depends on anatomy, procedural feasibility, expected course, and patient goals. Distinguish a symptom-directed intervention from an oncologic resection. A successful stent can provide substantial clinical benefit even though it does not eliminate the cancer or establish improved tumor control.
Apply it
A patient with metastatic pancreatic cancer has distressing pruritus and obstructive jaundice. Discuss biliary decompression to improve symptoms and facilitate the broader care plan rather than proposing pancreaticoduodenectomy solely to relieve the obstruction.
Common pitfall: Do not dismiss drainage because it is noncurative, or expose a patient to major tumor resection when a less burdensome intervention can meet the stated goal.
NCI: Pancreatic Cancer Treatment, Health Professional Version
33.How does incidental gallbladder cancer depth change postoperative assessment?
T1a gallbladder carcinoma invades the lamina propria, whereas T1b disease invades the muscular layer. Completely removed T1a disease with appropriate negative margins can be adequately treated by simple cholecystectomy. For incidental T1b disease, review pathology and margins, obtain staging imaging, and assess operative fitness. The AHPBA-sponsored society consensus recommends completion oncologic resection for medically fit patients without advanced disease precluding curative surgery. This includes regional portal lymphadenectomy and hepatic resection sufficient to achieve R0 clearance, such as a liver-bed wedge or an appropriate segment IVb/V resection. Routine major hepatectomy and routine extrahepatic bile duct removal are unnecessary; bile duct resection is reserved for obtaining negative margins when required. Prospective evidence is limited, and NCI notes continuing controversy over the extent of surgery for T1b disease.
Apply it
An incidental carcinoma confined to the lamina propria with negative margins represents the favorable T1a situation. If review instead confirms muscular invasion, stage the patient and assess fitness for completion resection with portal lymphadenectomy and adequate hepatic clearance. A negative cystic duct margin does not itself require bile duct removal.
Common pitfall: Do not group all T1 tumors into one postoperative plan. The T1b transition warrants consideration of completion oncologic surgery, but neither muscular invasion nor the goal of R0 clearance automatically justifies major hepatectomy or bile duct resection.
NCI: Gallbladder Cancer Treatment, Health Professional Version · Gallbladder Cancer: expert consensus statement - PMC
Sarcoma10%
34.Why must a suspected soft tissue sarcoma biopsy be planned?
Biopsy should establish a diagnosis while preserving the ability to perform definitive oncologic resection. Image-guided core sampling is often useful, and the biopsy route should be coordinated with the team that would remove the tumor. A poorly placed incision or tract can contaminate additional tissue compartments and complicate limb-preserving surgery. Imaging before biopsy helps define extent and select representative tissue. The goal is adequate diagnosis with minimal disruption of future operative planes, not simply the fastest access to the mass.
Apply it
A patient has a deep enlarging thigh mass suspicious for sarcoma. Obtain appropriate imaging and coordinate a core biopsy route with the sarcoma team before attempting an unplanned excision through a convenient transverse incision.
Common pitfall: A mass that appears easy to remove can still be sarcoma; unplanned excision may create contaminated margins and require a more extensive subsequent operation.
NCI: Soft Tissue Sarcoma Treatment, Health Professional Version
35.Which features determine FNCLCC soft tissue sarcoma grade?
The FNCLCC grading system incorporates tumor differentiation, mitotic activity, and tumor necrosis. Together these features estimate biologic aggressiveness and contribute to recurrence and metastatic risk assessment. Grade is distinct from anatomic stage, tumor size, and margin status, although those also affect management. A large low-grade lesion and a smaller high-grade lesion therefore cannot be treated as biologically identical. The report should identify the grading framework rather than using an unexplained adjective as a substitute for its components.
Apply it
A sarcoma report describes poor differentiation, numerous mitoses, and substantial necrosis. Recognize why these findings increase grade and influence treatment discussions, while separately reviewing tumor size, depth, site, and resection margins for the complete risk assessment.
Common pitfall: Do not define grade using size alone, or confuse a microscopically negative margin with evidence that the tumor has low metastatic potential biologically.
NCI: Soft Tissue Sarcoma Treatment, Health Professional Version
36.How can limb preservation remain oncologically appropriate in sarcoma?
Limb-sparing surgery aims to remove a soft tissue sarcoma with appropriate margins while retaining useful function. Radiation can contribute to local control in selected patients, especially when local recurrence risk is substantial. The decision depends on tumor relationships to critical structures, achievable clearance, reconstruction, and expected function. Amputation is not automatically required because a tumor is malignant or large. Conversely, preserving a limb without adequate oncologic clearance or useful function does not fulfill the purpose of conservation.
Apply it
An extremity sarcoma can be removed with planned reconstruction and acceptable margins while preserving a functional limb. Discuss limb-sparing multidisciplinary treatment, including radiation when indicated, rather than selecting amputation solely because the tumor is high grade.
Common pitfall: Do not equate an anatomically retained limb with a successful functional result, or assume radiation can compensate for any degree of gross residual tumor.
NCI: Soft Tissue Sarcoma Treatment, Health Professional Version
37.Why does GIST mutation testing matter before imatinib treatment?
Gastrointestinal stromal tumors commonly depend on altered KIT or PDGFRA signaling, but sensitivity to kinase inhibition depends on the specific alteration. PDGFRA D842V is a key example of resistance to imatinib. Histologic diagnosis alone therefore does not guarantee that imatinib will be effective. Molecular assessment is especially important when systemic therapy is intended to reduce a difficult tumor before surgery or reduce recurrence risk afterward. The relevant distinction is mutation-specific sensitivity, not simply membership in the GIST category.
Apply it
A large gastric GIST would require extensive surgery, prompting consideration of preoperative imatinib. Review molecular findings first; a PDGFRA D842V result changes the rationale for that proposed treatment and requires a different multidisciplinary strategy.
Common pitfall: Do not interpret KIT immunostaining as proof of imatinib sensitivity, or begin prolonged preoperative treatment without considering whether the identified driver is resistant.
NCI: Gastrointestinal Stromal Tumors Treatment, Health Professional Version
38.How do GIST surgical principles differ from routine nodal cancer surgery?
Localized GIST surgery prioritizes complete removal with an intact tumor capsule and avoidance of rupture. Routine formal lymphadenectomy is generally unnecessary because nodal spread is uncommon in typical adult GIST. This differs from the regional nodal principles used for many gastrointestinal adenocarcinomas. The operation should achieve appropriate clearance without unnecessary organ sacrifice when a limited resection is oncologically sound. Tumor handling matters because spillage or rupture can substantially worsen recurrence risk even when the primary mass is removed.
Apply it
A localized gastric GIST can be removed by a limited gastric resection without violating its capsule. Plan careful intact removal rather than automatically adding a formal gastric adenocarcinoma-style lymphadenectomy or unnecessary total gastrectomy.
Common pitfall: Do not import every adenocarcinoma operation into GIST care, and do not trade capsule integrity for a smaller incision or technically easier tumor extraction.
NCI: Gastrointestinal Stromal Tumors Treatment, Health Professional Version
39.How are recurrence risk and mutation sensitivity used after GIST resection?
The AFIP/Miettinen framework estimates GIST recurrence risk using anatomic site, greatest tumor diameter, and mitotic activity. Gastric tumors generally have a lower risk than small-intestinal tumors with comparable size and mitotic activity. Tumor rupture is an additional major adverse finding that must be assessed separately because the AFIP table does not incorporate it. Report mitoses over a defined area, preferably 5 mm²; an unspecified number of high-power fields is unreliable because microscope field areas vary. Complete resection does not eliminate recurrence risk. Adjuvant imatinib is appropriate for high-risk tumors with an imatinib-sensitive mutation, while very-low-risk tumors generally undergo surveillance.
Apply it
Consider two localized GISTs resected completely without preoperative therapy. A 4 cm gastric GIST with three mitoses per 5 mm² and no rupture is very low risk by AFIP criteria; surveillance generally suffices. An 8 cm jejunal GIST with eight mitoses per 5 mm² and no rupture is high risk because of its intestinal site, larger size, and mitotic activity above five. If the jejunal tumor has an imatinib-sensitive KIT exon 11 mutation, offer adjuvant imatinib. An imatinib-resistant PDGFRA D842V mutation would preclude expecting benefit from that drug despite high recurrence risk.
Common pitfall: Do not classify risk from size or negative margins alone. Distinguish recurrence probability from drug sensitivity: a high-risk tumor can still be resistant to imatinib. Document rupture explicitly, and never assume that 50 high-power fields necessarily equal 5 mm² without knowing the microscope's measured field area.
NCI: Gastrointestinal Stromal Tumors Treatment, Health Professional Version
Peritoneal Malignancy7%
40.Why is residual disease central to ovarian cancer cytoreduction?
In advanced epithelial ovarian cancer, the amount of residual macroscopic disease after cytoreduction is strongly associated with outcome. When feasible with acceptable morbidity, the operative goal is complete gross resection rather than merely reducing the largest mass. Disease distribution, patient condition, surgical expertise, and systemic treatment planning determine feasibility. The association does not mean every patient benefits from unlimited operative escalation. The decision concerns both the probability of meaningful clearance and the burden required to achieve it.
Apply it
A patient with disseminated epithelial ovarian cancer is being considered for primary surgery. Assess whether complete gross resection is realistically achievable with acceptable morbidity rather than planning an operation whose only stated goal is substantial debulking.
Common pitfall: Do not use the volume removed as the main measure of success when substantial disease remains, or ignore morbidity while pursuing increasingly extensive procedures.
NCI: Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment
41.When can neoadjuvant chemotherapy precede ovarian cytoreduction?
Neoadjuvant chemotherapy followed by interval cytoreduction is an established strategy for selected advanced epithelial ovarian cancers when immediate extensive surgery is unlikely to achieve adequate clearance or would carry excessive risk. Tissue confirmation is needed before treating presumed advanced cancer. Response and fitness are reassessed before interval surgery. This sequence differs from abandoning surgery altogether: it uses systemic treatment to organize a safer or more effective overall pathway. Selection should consider resectability and patient condition together.
Apply it
A frail patient has biopsy-confirmed advanced epithelial ovarian cancer with extensive disease unlikely to be completely removed initially. Discuss neoadjuvant platinum-based treatment and reassessment for interval cytoreduction rather than forcing immediate maximal surgery.
Common pitfall: Do not begin chemotherapy solely from an unconfirmed imaging impression, or assume that every patient receiving neoadjuvant treatment will necessarily become a suitable surgical candidate.
NCI: Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment
42.How does appendiceal pseudomyxoma peritonei change operative planning?
Appendiceal mucinous neoplasms can disseminate mucin and neoplastic epithelium throughout the peritoneum, producing pseudomyxoma peritonei. Pathology must distinguish acellular mucin from cellular disease and establish grade. Selected patients with peritoneal involvement merit assessment for cytoreductive surgery, often with intraperitoneal chemotherapy, at an experienced center. The objective is removal of macroscopic disease when feasible; appendectomy alone does not address established disseminated tumor. Histology, disease distribution, and fitness determine the strategy. [ASCRS appendiceal guideline](https://www.ascrsu.com/ascrs/repview?name=2_2851107_PDF&type=784-156)
Apply it
Appendectomy reveals a mucinous neoplasm, and imaging shows extensive peritoneal mucin. Obtain expert pathology review and assess peritoneal disease before proposing a routine completion colectomy as definitive treatment.
Common pitfall: Do not assume all extra-appendiceal mucin has identical risk, or that right colectomy alone clears diffuse peritoneal involvement.
43.When can colorectal peritoneal metastases enter a cytoreductive pathway?
Selected fit patients with colorectal peritoneal metastases, no extraperitoneal metastases, and disease amenable to complete macroscopic resection may be considered for cytoreductive surgery with systemic treatment in an experienced center. Selection depends on distribution and achievable clearance, not merely the presence of peritoneal disease. The PRODIGE 7 trial did not show an overall-survival benefit from adding its short-duration oxaliplatin HIPEC regimen to cytoreduction and found more later postoperative morbidity. Its result does not establish equivalence among all HIPEC regimens or primary tumors. [ASCO metastatic colorectal guideline](https://doi.org/10.1200/jco.22.01690)
Apply it
A fit patient has isolated, limited colorectal peritoneal implants that appear completely removable. Refer for specialist cytoreductive assessment, explaining that surgery and the addition of a particular HIPEC regimen are separate evidence questions.
Common pitfall: Do not extrapolate an appendiceal treatment pathway automatically to colorectal disease, or assume intraperitoneal chemotherapy compensates for unresectable macroscopic tumor.
Thoracic5%
44.How do EUS and PET-CT answer different esophageal staging questions?
Endoscopic ultrasound is useful for assessing esophageal wall invasion and regional nodes, whereas PET-CT contributes to identifying metabolically active distant disease. Their roles are complementary. A locally resectable appearance does not exclude metastasis, and a negative distant staging study does not establish superficial wall invasion. Suspicious findings that would change a curative plan may require confirmation. The discriminating question is whether the missing information concerns local depth and regional anatomy or disease outside the proposed locoregional treatment field.
Apply it
An esophageal cancer appears confined on conventional imaging, but its wall depth remains uncertain. Use EUS for local staging; use PET-CT to investigate occult distant spread rather than expecting either study to answer both questions equally.
Common pitfall: Do not replace local staging with a negative PET-CT, or proceed to a major curative operation without resolving a credible finding of distant disease.
NCI: Esophageal Cancer Treatment, Health Professional Version
45.How does lung expansion guide treatment of malignant pleural effusion?
For symptomatic malignant pleural effusion, ultrasound-guided therapeutic thoracentesis can establish whether drainage improves dyspnea and whether the lung expands. With expandable lung, either an indwelling pleural catheter or chemical pleurodesis is a reasonable definitive option. With nonexpandable lung or failed pleurodesis, an indwelling catheter is generally favored because pleurodesis requires pleural apposition. Asymptomatic patients ordinarily do not require therapeutic drainage solely because malignant fluid is present. [ATS/STS/STR guideline](https://www.thoracic.org/statements/resources/lcod/mgmt-of-mpe-guideline.pdf)
Apply it
Drainage relieves a patient's breathlessness, but the lung remains nonexpanded and fluid recurs. Discuss an indwelling pleural catheter rather than routine talc pleurodesis.
Common pitfall: Do not select pleurodesis without assessing expansion, or assume every patient's dyspnea is caused entirely by the effusion.
46.Which early esophageal cancers can be treated endoscopically?
For Barrett-associated adenocarcinoma, complete endoscopic resection of T1a disease with well or moderate differentiation and no lymphovascular invasion supports a curative endoscopic pathway, including management of remaining Barrett epithelium. Selected T1b adenocarcinomas with submucosal invasion no deeper than 500 micrometers, favorable differentiation, and no lymphovascular invasion may also qualify for expert-center treatment with structured follow-up. Squamous carcinoma uses separate criteria: an en bloc R0 lesion limited to epithelium or lamina propria, no deeper than m2, without lymphovascular invasion and with favorable histology is a low-risk example. [ESGE Barrett guideline](https://www.esge.com/diagnosis-and-management-of-barrett-esophagus); [ESGE superficial-lesion guideline](https://www.esge.com/endoscopic-submucosal-dissection-update-2022)
Apply it
An R0 Barrett-associated T1a adenocarcinoma is moderately differentiated without lymphovascular invasion. Endoscopic management is reasonable. A positive deep margin or unfavorable invasion findings requires restaging and discussion of additional treatment.
Common pitfall: Do not transfer the adenocarcinoma 500-micrometer criterion to squamous carcinoma, or equate technical removal with adequate nodal-risk control.
NCI: Esophageal Cancer Treatment, Health Professional Version
Upper Gastrointestinal8%
47.How should gastric tumor location determine the extent of gastrectomy?
The extent of gastrectomy should achieve adequate oncologic margins and regional nodal treatment while preserving stomach when appropriate. A distal tumor may be suitable for subtotal resection, whereas proximal or diffuse involvement may require a more extensive operation. Removing the entire stomach is not intrinsically superior when a lesser resection achieves the relevant oncologic objectives. Tumor location, growth pattern, margin feasibility, and nodal assessment matter more than a universal preference for either maximal preservation or maximal removal.
Apply it
A resectable distal gastric adenocarcinoma can be removed with appropriate margins and regional lymphadenectomy by subtotal gastrectomy. Discuss that option rather than assuming total gastrectomy is necessary for every patient with gastric cancer.
Common pitfall: Do not preserve stomach at the cost of inadequate margins, or choose total gastrectomy solely from the belief that a larger operation always improves cancer outcomes.
48.Which resectable gastric cancers support perioperative chemotherapy, and what is a representative treatment sequence?
A fit patient with resectable, nonmetastatic gastric adenocarcinoma staged cT2 or higher or clinically node-positive has a concrete indication to consider perioperative systemic treatment. These were eligibility criteria in the [FLOT4 trial](https://pubmed.ncbi.nlm.nih.gov/30982686/). FLOT comprises fluorouracil, leucovorin, oxaliplatin, and docetaxel. The established chemotherapy sequence uses four cycles at 2-week intervals before surgery, gastrectomy with regional lymphadenectomy, and four postoperative cycles as recovery and tolerance permit. Systemic treatment addresses occult metastatic disease that technically complete resection cannot eradicate. Selected superficial cT1aN0 cancers may instead qualify for endoscopic resection. FLOT is an established chemotherapy example; biomarker findings, including MMR/MSI status, and contemporary perioperative immunotherapy evidence also inform regimen selection.
Apply it
A fit patient has cT3N1M0 gastric adenocarcinoma. After staging and nutritional assessment, an established approach is four preoperative FLOT cycles, reassessment, curative gastrectomy with regional lymphadenectomy, and four postoperative cycles if tolerated. This patient meets both the depth and nodal criteria supporting perioperative treatment.
Common pitfall: Anatomical resectability does not establish that surgery alone adequately treats systemic risk. Conversely, do not apply this sequence automatically to every superficial cancer. Treatment intensity and postoperative completion depend on fitness, nutrition, toxicity, and recovery.
49.Which gastric cancer HER2 results support conventional HER2-directed treatment?
Conventional HER2-positive gastric or gastroesophageal junction adenocarcinoma treatment selection includes IHC 3+ or IHC 2+ with positive in situ hybridization demonstrating amplification. IHC 2+ alone is equivocal and requires confirmatory testing; it does not establish HER2-positive eligibility. In appropriate advanced disease, confirmed positivity can support a trastuzumab-containing systemic regimen. Disease setting and other biomarkers also determine the complete regimen.
Apply it
A metastatic gastric adenocarcinoma is HER2 IHC 2+. Obtain in situ hybridization before classifying it as HER2 positive. A positive amplification result supports consideration of trastuzumab; a negative result does not satisfy this conventional HER2-positive definition.
Common pitfall: Do not treat equivocal protein staining as confirmed amplification, or assume every gastric cancer benefits from trastuzumab without the relevant biomarker result.
50.What operation is appropriate for localized small bowel adenocarcinoma?
Localized small bowel adenocarcinoma is treated with oncologic resection when feasible, including the involved bowel and appropriate regional mesentery and nodes. The required operation varies by site; some duodenal tumors require pancreaticoduodenectomy because of their relationship to adjacent structures. A jejunal lesion may be suitable for segmental resection. Distinguish adenocarcinoma from other small bowel tumors, because GIST, lymphoma, and neuroendocrine tumors have different biologic and operative considerations despite occupying the same organ.
Apply it
A fit patient has a localized jejunal adenocarcinoma without distant spread. Plan segmental oncologic bowel resection with regional mesenteric nodal assessment, rather than using a GIST-style operation that intentionally omits routine nodal evaluation.
Common pitfall: Do not let the phrase small bowel tumor erase histologic distinctions, or assume that the same segmental operation is appropriate for every duodenal location.
NCI: Small Intestine Cancer Treatment, Health Professional Version
51.How should enteral stenting and surgical bypass be selected for unresectable malignant gastric outlet obstruction?
Enteral self-expandable metal stenting generally permits faster resumption of oral intake and a shorter initial hospitalization than surgical gastrojejunostomy, but recurrent obstruction and reintervention are more frequent. Surgical gastrojejunostomy requires greater initial recovery and provides more durable relief for suitable operative candidates with longer anticipated survival. The 2021 ASGE guideline suggests stenting for poor surgical candidates with life expectancy under six months and for patients prioritizing rapid eating and discharge; it favors surgical gastrojejunostomy for patients with good performance status and anticipated survival over six months. This is conditional guidance supported by low-quality evidence, not a universal survival cutoff.
Apply it
A frail patient with unresectable gastric cancer, ECOG performance status 3, an estimated survival of two months, and a priority of returning home quickly generally favors an enteral stent if the obstruction can be traversed. A patient with ECOG performance status 1, acceptable operative risk, and anticipated survival beyond a year who prioritizes avoiding repeat procedures generally favors gastrojejunostomy. Both examples assume a single mechanical outlet obstruction and patent downstream bowel; additional distal obstruction would undermine either procedure's ability to restore eating.
Common pitfall: Rapid initial recovery and long-term durability are different outcomes. Stent occlusion can result from tumor ingrowth, overgrowth, or food impaction, while migration can also require another intervention. Bypass avoids reliance on patency through the tumor but carries operative morbidity and possible delayed gastric emptying. Discuss these tradeoffs alongside prognosis, anatomy, and recovery priorities.
NCI: Gastric Cancer Treatment, Health Professional Version · ASGE | ASGE guideline on the role of endoscopy in the management of benign and malignant gastroduodenal obstruction
Medical Oncology2%
52.How should fever with suspected neutropenia change an elective surgical plan?
After chemotherapy, a single oral temperature of at least 38.3°C, or at least 38.0°C sustained for one hour, with ANC below 500/µL or expected to fall below that level within 48 hours meets standard febrile-neutropenia criteria. Treat this as an urgent infection problem: assess hemodynamics, obtain blood counts and cultures without delaying treatment, and begin prompt empiric antibiotics. Initial antibacterial treatment should start within one hour of triage. High-risk or unstable patients require inpatient intravenous treatment with antipseudomonal coverage. [IDSA guideline](https://www.idsociety.org/practice-guideline/neutropenic-patients-with-cancer/); [ASCO–IDSA update](https://www.idsociety.org/practice-guideline/fever-and-neutropenia-in-adults-with-cancer/)
Apply it
A patient scheduled for elective cancer resection develops a temperature of 38.5°C and ANC of 300/µL after chemotherapy. Postpone elective surgery and urgently assess and treat possible infection; reassess operative readiness after recovery.
Common pitfall: Do not wait for a localizing symptom or a positive culture. Neutropenia can blunt inflammatory findings, and antipyretics can obscure fever without treating infection.
Infection and Neutropenia and Cancer Treatment - Side Effects - NCI
Pathology2%
53.Why do specimen orientation and inked surfaces matter in margin interpretation?
Margin assessment depends on relating tumor to the true resection surfaces and communicating where those surfaces lie anatomically. Orientation and inking allow a positive margin to be localized and distinguished from a close negative margin. In breast conservation, tumor on ink has a different implication from a small measured distance without ink involvement. Sampling and processing methods influence what can be concluded, so a report should be interpreted with awareness of how the specimen was handled and labeled.
Apply it
A breast excision report identifies tumor on the superior inked surface. Use the specimen orientation to discuss targeted additional excision, rather than interpreting the result as an unspecified close margin or removing tissue from an unrelated cavity surface.
Common pitfall: Do not treat close and ink-positive margins as synonyms, or assume an unoriented specimen can identify the exact anatomic direction requiring additional surgery.
SSO–ASTRO Consensus Guideline: Margins for Breast-Conserving Surgery
Radiation Oncology1%
54.Why does radiation complement breast-conserving surgery?
Surgery removes the identified breast tumor, while whole-breast irradiation reduces the risk from residual microscopic disease in the conserved breast. This complementary mechanism explains why the invasive-cancer no-ink margin standard is defined within a treatment setting that includes irradiation. Radiation is not a substitute for knowingly leaving a positive surgical margin. Selected omission strategies require their own eligibility criteria and discussion; the contribution of radiation should not be inferred solely from a small tumor or a negative margin.
Apply it
A patient with a negative-margin invasive breast cancer asks why radiation remains part of conservation. Explain its role in reducing recurrence from microscopic disease, while assessing whether any specific evidence-based omission pathway actually applies to her situation.
Common pitfall: Do not use planned radiation to dismiss tumor on ink, or assume that negative margins alone establish that postoperative irradiation has no additional local-control value.
SSO–ASTRO Consensus Guideline: Margins for Breast-Conserving Surgery · NCI: Breast Cancer Treatment, Health Professional Version
Clinical Trials2%
55.How is number needed to treat calculated from absolute risk?
Number needed to treat is the reciprocal of absolute risk reduction for a specified outcome and time horizon. Subtract the treated event risk from the comparison risk, express that difference as a proportion, and take its reciprocal. For example, risks of 20% and 15% produce a 0.05 absolute reduction and an NNT of 20. Relative risk reduction answers a different question. Interpretation also requires attention to uncertainty, treatment harms, baseline risk, and whether the outcome matters clinically.
Apply it
A hypothetical trial reports three-year recurrence of 18% with standard care and 12% with treatment. Calculate an absolute reduction of 0.06 and an NNT of 16.7, conventionally rounded up to 17 for that endpoint and period.
Common pitfall: Do not invert the relative risk reduction, mix percentages with proportions, or present an NNT without the outcome and follow-up period that define it.
56.Why does intention-to-treat analysis preserve randomized comparisons?
Intention-to-treat analysis evaluates participants according to their randomized assignment rather than regrouping them by treatment actually received. This preserves the comparison created by randomization and reduces bias from post-randomization decisions related to prognosis or tolerance. Nonadherence can dilute an estimated treatment effect, but excluding nonadherent patients can create a different bias. Missing outcome data still require careful methods; the intention-to-treat principle does not magically recover unobserved outcomes or make incomplete follow-up harmless.
Apply it
In a surgical trial, several participants assigned to surgery decline it after randomization. For the primary intention-to-treat comparison, retain their randomized group assignment and examine follow-up completeness rather than moving them into the nonsurgical group.
Common pitfall: An as-treated analysis can break randomization when treatment receipt reflects patient condition; labeling an analysis intention-to-treat does not resolve substantial missing outcome data.
End of Life/Palliative Care2%
57.When should palliative care be integrated into cancer treatment?
Palliative care addresses physical symptoms, emotional distress, practical concerns, spiritual needs, and communication about goals. It can accompany active cancer-directed treatment and is not restricted to the final days of life. Early involvement is particularly useful when symptom burden or decision complexity is substantial. The relevant trigger is unmet need, not proof that all anticancer options have ended. Distinguish this broad supportive approach from hospice eligibility and from a decision to stop every disease-directed intervention.
Apply it
A patient beginning treatment for metastatic cancer has pain, insomnia, family distress, and uncertainty about priorities. Offer concurrent palliative care while oncology treatment proceeds, using the patient's goals to coordinate symptom management and future decisions.
Common pitfall: Do not postpone palliative care until treatment is exhausted, or interpret a referral as an automatic decision to abandon systemic therapy or useful procedures.
Systems-Based Practice2%
58.How should a surgical team respond to a site discrepancy?
A surgical time-out is an active team verification of the patient, intended procedure, and correct site using consistent source information. A discrepancy requires resolution before proceeding. Passive agreement or reliance on one person's memory weakens the process, especially when scheduling records, consent, and site marking conflict. The safety mechanism is shared confirmation and a genuine opportunity to stop the workflow. It is not the presence of a completed checkbox or the seniority of the person expressing confidence.
Apply it
During the time-out for excision of a skin malignancy, the consent and site mark identify opposite sides. Stop progression, reconcile the discrepancy with the appropriate records and patient involvement when possible, and proceed only after verification.
Common pitfall: Do not let schedule pressure or a senior clinician's recollection override unresolved documentation, and do not treat a signed form as proof that the intended site is correct.
AHRQ PSNet: Wrong-Site, Wrong-Procedure, and Wrong-Patient Surgery
59.Why should root cause analysis produce system changes?
Root cause analysis examines how interacting processes, communication, equipment, staffing, and organizational conditions contributed to a safety event. Its purpose is learning and prevention rather than identifying a single person to blame. A useful analysis links contributing factors to specific corrective actions and measures whether those actions work. Education alone may be insufficient when the workflow repeatedly enables the same error. Distinguish explaining what happened from changing the conditions that made recurrence possible.
Apply it
After a specimen-labeling near miss, the team identifies confusing labels and interrupted handoffs. Redesign label verification and handoff steps, assign responsibility, and monitor subsequent discrepancies rather than ending the review with a reminder to be careful.
Common pitfall: Do not mistake a detailed event narrative for an effective improvement plan, or assume staff retraining will correct a persistent flaw in the surrounding system.
Community Outreach1%
60.How can screening outreach be evaluated without hiding access disparities?
Screening outreach should distinguish the population eligible for screening from those invited, those participating, and those completing necessary follow-up. Different denominators answer different questions and can conceal access gaps when combined carelessly. Comparing completion proportions across relevant groups can identify where navigation or service access deserves investigation. A higher uptake rate does not alone prove mortality benefit or net benefit; those require separate outcome evidence. Clear denominators connect community activity to measurable access rather than attendance counts alone.
Apply it
A program invites 200 eligible patients, and 120 complete screening. Report 60% completion among those invited, then examine group-specific completion and follow-up instead of reporting only the 120 participants as evidence that access is equitable.
Common pitfall: Do not infer screening effectiveness from participation alone, or let an overall average conceal a subgroup whose diagnostic follow-up is much less likely to be completed.
ABS: CGSO Exam Blueprint, Updated 01/2023 · Cancer Screening Overview (PDQ®) - NCI
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Prioritize Hepatopancreatobiliary, Breast, Colorectal, Cutaneous, and Sarcoma while retaining scheduled study of every smaller domain.
- For each cancer, connect diagnostic evidence to stage, resectability, physiologic fitness, operative choice, and treatment sequence.
- Contrast close negative margins with positive margins, microscopic nodal disease with clinically apparent disease, and technical resectability with physiologic operability.
- Practise biomarker-to-treatment reasoning: hormone receptors, HER2, BRAF, RET, mismatch repair, and GIST driver mutations answer different questions.
- Use the pancreatic fistula, colorectal surveillance, and breast lymphedema examples to practise recognition cues, the action they trigger, and its purpose. Add other disease-specific complications, follow-up pathways, and rehabilitation needs from the full outline.
- Interpret absolute benefits, randomized comparisons, and safety interventions precisely rather than memorizing isolated terminology.
A practical preparation plan
1. Map the complete scope
Read the official outline and mark each disease and patient-care dimension as secure, uncertain, or unstudied. Use this guide for selected decision principles and add the omitted topics to a separate study schedule.
2. Build paired decision comparisons
Compare two cases that differ by one decisive finding: ink involvement, rectal margin threat, liver decompensation, a resistant GIST mutation, or a suspicious additional breast lesion. State exactly why the finding changes the plan.
3. Work through multidisciplinary sequences
For representative cancers, write the order of staging, tissue confirmation, systemic treatment, surgery, radiation, and reassessment. Include the physiologic or oncologic reason for every transition. Extend the pathway through complication recognition, surveillance, and functional recovery.
4. Use the questions diagnostically
Answer all 20 questions before reviewing explanations. For each error, identify the decisive cue you missed and explain why each alternative fails. These drills measure learning needs rather than likelihood of passing.
5. Recall and revisit
Use the flashcards for spaced recall, then apply each recalled principle to a different clinical presentation. Recheck uncertain clinical details in the relevant primary reference and review the ABS outline for breadth.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABS: CGSO Qualifying Examination
- ABS: Exam Content Outlines
- ABS: Complex General Surgical Oncology Exam Blueprint
- ABS: CGSO Exam Blueprint, Updated 01/2023
- SSO–ASTRO Consensus Guideline: Margins for Breast-Conserving Surgery
- NCI: Breast Cancer Treatment, Health Professional Version
- NCI: Colon Cancer Treatment, Health Professional Version
- NCI: Rectal Cancer Treatment, Health Professional Version
- NCI: Melanoma Treatment, Health Professional Version
- NCI: Thyroid Cancer Treatment, Health Professional Version
- NCI: Pheochromocytoma and Paraganglioma Treatment, Health Professional Version
- NCI: Primary Liver Cancer Treatment, Health Professional Version
- NCI: Pancreatic Cancer Treatment, Health Professional Version
- NCI: Gallbladder Cancer Treatment, Health Professional Version
- NCI: Soft Tissue Sarcoma Treatment, Health Professional Version
- NCI: Gastrointestinal Stromal Tumors Treatment, Health Professional Version
- NCI: Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment
- NCI: Esophageal Cancer Treatment, Health Professional Version
- NCI: Gastric Cancer Treatment, Health Professional Version
- NCI: Small Intestine Cancer Treatment, Health Professional Version
- National Library of Medicine: Numbers Needed To Treat
- FDA/ICH E9: Statistical Principles for Clinical Trials
- NCI: Palliative Care in Cancer
- AHRQ PSNet: Wrong-Site, Wrong-Procedure, and Wrong-Patient Surgery
- AHRQ PSNet: Root Cause Analysis
- Male Breast Cancer Treatment (PDQ®) - NCI
- Management of Rectal Cancer (2020) | ASCRS Toolkit - FREE Resources
- Infection and Neutropenia and Cancer Treatment - Side Effects - NCI
- Cancer Screening Overview (PDQ®) - NCI
- International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment - PMC
- Lymphedema (PDQ®) - NCI
- park-et-al-2025-sentinel-lymph-node-biopsy-in-early-stage-breast-cancer-asco-guideline-update.pdf
- Colon and Rectal Cancer Follow-Up Care Expanded Version
- Skin Cancer Treatment (PDQ®) - NCI
- Lab Dictionary | View
- Screening and Surveillance for Colorectal Cancer
- What's New in v2018 : RADS - Reporting and Data Systems Support
- Client Challenge
- Gallbladder Cancer: expert consensus statement - PMC
- mgmt-of-mpe-guideline.pdf
- 2023_a-2176-2440.pdf
- repview
- ASGE | ASGE guideline on the role of endoscopy in the management of benign and malignant gastroduodenal obstruction
- outpatient-management-of-fever-and-neutropenia.pdf
- ASCO/IDSA Clinical Practice Guideline Update for Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.